Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 7.8% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a clinical-stage gene editing company focused on CRISPR-based therapies. The overall market sentiment for gene editing companies has been positive due to the potential of revolutionary medical treatments.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 7.8% on Jan 8, 2025 15:13

• The downturn in NTLA stock might be attributed to profit-taking by investors following a recent uptrend.
• The recent announcement of inducement grants could have been seen as share dilution, prompting a sell-off.
• Investor wariness regarding regulatory policies on gene editing technologies could be adversely affecting the stock.
• In general, the current downward trend could be a short-term adjustment within the context of a promising industry outlook.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )

CAMBRIDGE, Mass, Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on January 1, 2025, it awarded inducement grants to three new ...

https://www.globenewswire.com/news-release/2025/01/06/3004494/0/en/Intellia-Therapeutics-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html

Trending Today

Sui ($SUI) Crypto Forecast: Up 8.6% Today

Fantom ($FTM) Crypto Forecast: Up 5.9% Today

Mantle ($MNT) Crypto Forecast: Up 5.5% Today

MANTRA ($OM) Crypto Forecast: Up 7.2% Today

Cardano ($ADA) Crypto Forecast: Up 5.0% Today

Heating Oil ($HEATOIL) Commodity Forecast: Up 5.0% Today

THORChain ($RUNE) Crypto Forecast: Down 9.4% Today

Ondo ($ONDO) Crypto Forecast: Up 7.5% Today

Memecoin ($MEME) Crypto Forecast: Up 5.0% Today

Notcoin ($NOT) Crypto Forecast: Up 5.1% Today

Intellia Therapeutics, Inc. Price History

13.08.2024 - NTLA Stock was up 7.6%

• Positive data from the Phase 2 study of NTLA-2002 for Hereditary Angioedema (HAE) was presented by Intellia Therapeutics.
• The encouraging results from the study likely instilled confidence in NTLA-2002 as an innovative therapy, potentially attracting investors.
• Speculations about positive outcomes from the upcoming presentation at the 2024 ACAAI Annual Scientific Meeting might have contributed to NTLA's bullish movement.
• This progress could be seen as a notable advancement in CRISPR-based therapies, driving increased interest in Intellia Therapeutics' shares.

04.08.2024 - NTLA Stock was down 6.8%

• The bearish movement in NTLA's stock could be attributed to profit-taking by investors after a recent bullish run.
• The inducement grants to new employees might have raised concerns about increased operating expenses, leading to a sell-off.
• Investors may be cautious about the competitive landscape in gene editing, with increased scrutiny on regulatory approvals and intellectual property rights.
• Overall, the market reaction could be a short-term adjustment rather than a reflection of the company's long-term growth prospects.

08.10.2024 - NTLA Stock was up 5.2%

• NTLA reported a Q3 loss but outperformed revenue estimates, demonstrating a strong financial performance.
• The market reacted positively, with investors focusing on the revenue beat over the earnings miss.
• Updates on the company's pipeline candidates likely boosted investor confidence in future growth opportunities.
• The bullish movement in NTLA's stock reflects market optimism towards its revenue performance and promising pipeline developments.

11.09.2024 - NTLA Stock was up 5.1%

• Releasing the new date for the investor webcast to discuss the NTLA-2002 Phase 2 data likely fueled positive anticipation and excitement among investors.
• Commencing the HAELO Phase 3 study of NTLA-2002, an investigational in vivo CRISPR gene editing treatment, indicates progress and potential future milestones for the company, enhancing investor confidence.
• These developments underscore Intellia Therapeutics' dedication to advancing its cutting-edge therapies, capturing investor attention and contributing to the bullish performance of the stock today.

24.09.2024 - NTLA Stock was down 19.7%

• The Phase 2 data release for NTLA-2002 in patients with hereditary angioedema (HAE) may have disappointed investors, resulting in a bearish movement in NTLA stock.
• Investor expectations for the study's results or developments may have been higher, leading to a sell-off.
• Market reactions suggest concerns about the effectiveness or commercial viability of NTLA-2002 for HAE treatment, impacting the stock price negatively.

29.09.2024 - NTLA Stock was down 5.3%

• NTLA witnessed significant bearish activity during the trading day.
• Bearish indicators in the options market possibly impacted the stock's decline.
• Disappointment among investors following the Phase 2 data release of NTLA-2002 for patients with hereditary angioedema (HAE) could have contributed to the negative market response.
• General market sentiment towards gene therapy companies may have also influenced the downward movement in Intellia Therapeutics' stock value.

08.00.2025 - NTLA Stock was down 7.8%

• The downturn in NTLA stock might be attributed to profit-taking by investors following a recent uptrend.
• The recent announcement of inducement grants could have been seen as share dilution, prompting a sell-off.
• Investor wariness regarding regulatory policies on gene editing technologies could be adversely affecting the stock.
• In general, the current downward trend could be a short-term adjustment within the context of a promising industry outlook.

27.10.2024 - NTLA Stock was up 5.8%

• Intellia Therapeutics (NTLA) saw a significant bullish movement after the FDA granted Regenerative Medicine Advanced Therapy (RMAT) status to its genome-editing therapy for hereditary transthyretin (ATTR) amyloidosis with polyneuropathy.
• Cathie Wood's bullish outlook on biologics and gene editing technologies may have also contributed to the positive sentiment surrounding Intellia Therapeutics, as investors are optimistic about the potential growth in this sector.
• The combination of positive regulatory developments and industry trends in biotechnology likely fueled the strong bullish movement in NTLA's stock today.

07.07.2024 - NTLA Stock was down 5.2%

• The bearish movement in NTLA stock could be attributed to profit-taking by investors who may have been disappointed by the company's second-quarter financial results.
• Despite the upcoming conference call to discuss earnings and company updates, investors might be cautious due to uncertainties surrounding the future prospects of CRISPR-based therapies.
• The focus on Cathie Wood stocks may have diverted attention and investment away from NTLA, leading to a decline in its stock price.
• It is essential for investors to conduct thorough research and analysis beyond following popular investor recommendations to make informed decisions in the market.

13.07.2024 - NTLA Stock was up 5.1%

• Despite Intellia falling short of estimates in Q2 earnings and revenues, the gene editing sector, including NTLA, is attracting attention for its potential in revolutionizing medicine and treating genetic disorders.
• The advancements in Intellia's clinical pipeline, mentioned during their earnings call, likely sparked investor optimism and contributed to the market movement.
• Although there were mixed results in earnings and revenue for Q2 2024, initially causing some stock price volatility, the positive outlook on gene editing technology appears to have overshadowed these concerns, leading to the recent market uptrend.

08.07.2024 - NTLA Stock was down 6.4%

• The bearish movement in NTLA stock could be attributed to investors focusing on the increased net loss reported despite the positive Phase 2 results for the HAE treatment.
• The market might be reacting to concerns about the company's cash position, even though it stands at $939.9M, as investors may be looking for stronger financial stability.
• Investors could be cautious about the biotech sector as a whole, given the risks and rewards associated with investing in stocks with promising pipelines, leading to a broader sell-off in NTLA.
• The mention of Cathie Wood stocks could have influenced market sentiment, with investors potentially shifting focus towards other opportunities, impacting the performance of NTLA negatively.

14.07.2024 - NTLA Stock was down 5.1%

• NTLA stock displayed a decline in value during the latest trading session.
• The company's Q2 earnings and revenues were below expectations, falling short of analyst predictions by a considerable margin.
• Despite advancements in its clinical pipeline highlighted during the earnings call, Intellia Therapeutics' financial performance for Q2 failed to meet investor expectations.
• The disappointing Q2 earnings and revenues for Intellia Therapeutics likely contributed to the negative movement in NTLA stock, as investor reaction to the missed estimates was unfavorable.